All News
Dual seropositivity and shared epitopes in RA: friends or foes?
Dual seropositivity (rheumatoid factor and/or anti-citrullinated protein antibodies) as well as shared epitope are known to be associated with poor prognosis and structural damage in RA.
Read Article
GOLMePsA RCT early naive PsA
Golimumab or PBO in addition to MTX+IM GCs
No difference wk52
ACR20 GOL 76% PBO 55%
MDA GOL 55% PBO 41%
PBO arm received higher GC dose
No new safety signal
@RheumNow AbstOP0148 #EULAR2024 https://t.co/bj7YNXhssm
Aurelie Najm AurelieRheumo ( View Tweet)
📺 Join @RheumNow, @Yuz6Yusof & I for the Daily Recap over on @YouTube
⏩ https://t.co/D3HZGUdi9t
⏰ TODAY 18:00 CEST
👋 See you there!
#EULAR2024
Mrinalini Dey DrMiniDey ( View Tweet)
Nationwide epi study of lymphoproliferative disorders in Sjogren's. All pts in France!
4 % prevalence
More in males and those with cryos and MGUS
#EULAR2024
@rheumnow
abst#OP0207 https://t.co/bEaWpTD7x3
Links:
Bella Mehta bella_mehta ( View Tweet)
Severe refractory Sjogrens - not in RCTs but some meds such as CD20 - Obinutuzumab, CART have been reported.
A summary of slides @RheumNow https://t.co/9HQRAj3rzt
Links:
Bella Mehta bella_mehta ( View Tweet)
CD40 and CD40L (CD154) inhibition
CD-40 monoclonal antibody
CD 40 Ligand blockade- Dazodalibep
@RheumNow https://t.co/n9CcrujVwa
Links:
Bella Mehta bella_mehta ( View Tweet)
#EULAR2024 POS0237 RNA-seq of muscle biopsy in inflammatory myopathy (IIM) showed distinct gene expressions underlying muscle damage between DM, Antisynthetase & PM. Potential targets for future therapeutics @RheumNow @IzukaShinji https://t.co/nf0pp2RhaE
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Current and future treatment in Sjogrens Syndrome @rheumnow #EULAR2024
Many failed trails - likely secondary to non validated outcomes.
3 major domains - sicca, extraglandular manifestations, constitutional https://t.co/cCYX1YCqG2
Links:
Bella Mehta bella_mehta ( View Tweet)
"T and B cells playing tennis" In Sjogren's Syndrome!
Thomas Dorner - #EULAR2024 @rheumnow https://t.co/Lum0A9cY9U
Bella Mehta bella_mehta ( View Tweet)
Isolated ⬆️ serum #IgG4 level:
💎💎💎 (Dr. Stone):
❓How high? >5x ULN ➡️PPV 75%‼️
❓Typical organ(s) involved?
❓Another explanation?
#eular2024
#rheumx
@eular_org
@RheumNow https://t.co/pm6wjvi2Vt
Links:
Artem Minalyan, MD, DABOM AMinalyan ( View Tweet)
Different clusters - subpopulations of Sjogrens syndrome may exist and getting patient input is important @RheumNow https://t.co/7v5MYzzotT
Links:
Bella Mehta bella_mehta ( View Tweet)
How to assess treatment in Sjogren's Syndrome
#EULAR2024 @RheumNow
1) define the target population
2) standardize inclusion criteria
3) Restricting ESSDAI domain to 5 domains
4) Correct endpoint choice https://t.co/m7DvZdpuZa
Links:
Bella Mehta bella_mehta ( View Tweet)
#EULAR2024 POS0223 UK multicentre data showed real-world avacopan use in #vasculitis differed from RCT: it was started later;often combined w other IS; GC tapering varied; 20% had eGFR<15. Compared to historical cohort of GC taper, OR of clinical response in AVA was 3.6 @RheumNow https://t.co/MP3OrRSJ0U
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Sjogrens Syndrome - bench to bedside session.
#EULAR2024 @RheumNow
Important to concentrate on non infiltrative patients. (to find different / early phenotypes?) https://t.co/ezFkX6CW8l
Links:
Bella Mehta bella_mehta ( View Tweet)
Real world data of safety profiles in SpA and Secukinumab- in all age groups #POS0199 #EULAR2024 @RheumNow https://t.co/q0FFP2SMLl
Bella Mehta bella_mehta ( View Tweet)
Very contradictory study in Axial SpA- no evidence of better drug retention or better treatment response compared to a later start of treatment.
Data of early and very early disease. POs0204 #EULAR2024 @RheumNow https://t.co/6ci6xfyRmq
Bella Mehta bella_mehta ( View Tweet)
What happens when RA patients only on csDMARDs want to stop their meds?
in BIO-FLARE, only half flared within 6mo of stopping all csDMARDs suddenly. They’ve got a clinical predictive model. Many milder patients ask, and could benefit!
#EULAR2024 POS0068 John Isaacs @RheumNow https://t.co/B7ZjP5Pj70
Links:
David Liew drdavidliew ( View Tweet)
#EULAR2024 OP0206 In a cohort study, of pts with #lupus nephritis, 81% tapered IS ~32 mths post-renal response. Of this, 17% flared. Strategies for safe tapering: ensure CR is achieved, low SLEDAI-2K at 12mths, low SLEDAI-2K & on HCQ at the time of tapering initiation @RheumNow https://t.co/hAMAdsL7Jn
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Risk of developing RA increased in antibody double-positive and single-positive compared to seronegative individuals. Highest risk in double-positive in first year. Single-positive increased risk of RA for up to five years after testing. In double-positive the risk remained… https://t.co/XLDHK4d4AE https://t.co/3Ek8knGExU
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Biosimilar uptake across the world.
Interesting that rich countries use more biosimilars - presumably because they have bargaining power - and that means they can access even better pricing.
#EULAR2024 POS0597 Leiden @RheumNow https://t.co/wZgA0JH5uu
David Liew drdavidliew ( View Tweet)
